文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

直肠癌全程新辅助治疗对后续肝转移及化疗相关肝损伤的影响

Total neoadjuvant therapy for rectal cancer: Implications for subsequent liver metastases and chemotherapy-associated liver injury.
PubMed 文献 · Surgery · 2026-04-01

单中心2014–2024年286例直肠癌肝转移行肝切除患者中,30例接受全程新辅助治疗(TNT)、256例未接受。TNT组中位总生存48.7个月,显著低于非TNT组的99.5个月(P=.01);TNT组脂肪变或脂肪性肝炎发生率30.8%,高于非TNT组的8.7%(P=.002),而肝窦损伤率无显著差异。

要点

  • 直肠癌TNT后出现肝转移者,肝切除后总生存显著更差。
  • TNT组脂肪变或脂肪性肝炎发生率显著升高。
  • 肝窦损伤率在TNT与否之间无显著差异。

核心结论

  • 直肠癌TNT期间或之后发生肝转移者,肝切除后总生存显著差于未接受TNT者。
  • TNT组脂肪变或脂肪性肝炎发生率更高,肝窦损伤率无显著差异。

研究设计与样本

  • 单中心前瞻性维护数据库查询,纳入2014–2024年因直肠癌肝转移行肝切除的患者。
  • 共286例,其中30例接受TNT、256例未接受TNT;复习手术病理报告评估背景肝组织学改变。

主要发现

  • TNT组中位总生存48.7个月,非TNT组99.5个月,P=.01。
  • 多变量分析中TNT仍为更差总生存的独立预测因素(HR 0.41,95%CI 0.22-0.79,P=.008)。
  • 肝窦损伤率TNT组26.9% vs 非TNT组32.9%,P=.69。
  • 脂肪变或脂肪性肝炎率TNT组30.8% vs 非TNT组8.7%,P=.002。

临床怎么用

  • 直肠癌TNT后出现肝转移者行肝切除前,应评估其总生存可能更差并向患者说明。
  • TNT史患者肝切除前需关注背景肝脂肪变或脂肪性肝炎,纳入围术期风险评估。

局限性

  • 为初步分析,TNT组样本量小(30例),需进一步研究。
  • 单中心回顾性数据库查询,未明确TNT组生存更差的相关因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total neoadjuvant therapy for localized rectal cancer entails delivery of all systemic chemotherapy and pelvic radiation before proctectomy to improve pathologic response, disease-free survival, and potentially organ preservation. In patients who develop liver metastases during or after total neoadjuvant therapy, the effects of total neoadjuvant therapy on patient outcomes and chemotherapy-associated liver injury are unknown. METHODS: A single-institution prospectively maintained database was queried for patients who underwent hepatectomy for metastatic rectal cancer, with or without total neoadjuvant therapy between 2014 and 2024. Surgical pathology reports were reviewed for histologic changes in the background liver. RESULTS: Among 286 patients undergoing hepatectomy for metastatic rectal cancer, 30 patients received total neoadjuvant therapy, and 256 patients did not receive total neoadjuvant therapy. Overall survival was significantly lower among patients in the total neoadjuvant therapy group (median overall survival 48.7 months, total neoadjuvant therapy vs 99.5 months, non-total neoadjuvant therapy, P = .01). On multivariable analysis, total neoadjuvant therapy remained an independent predictor of worse overall survival (hazard ratio 0.41, 95% confidence interval 0.22-0.79, P = .008). Sinusoidal injury rates were not significantly different with or without total neoadjuvant therapy (26.9% total neoadjuvant therapy vs 32.9% non-total neoadjuvant therapy, P = .69). Patients who received total neoadjuvant therapy had significantly higher rates of steatosis or steatohepatitis (30.8% total neoadjuvant therapy vs 8.7% non-total neoadjuvant therapy, P = .002). CONCLUSION: In this preliminary analysis, patients who developed liver metastases during or after total neoadjuvant therapy for rectal cancer had significantly worse overall survival after hepatectomy than patients who did not receive total neoadjuvant therapy. Steatosis and steatohepatitis rates were higher with total neoadjuvant therapy. Further study is needed to identify factors associated with worse outcomes in patients who undergo hepatectomy after total neoadjuvant therapy.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Ito K, Jain AJ, Newhook TE, et al. Total neoadjuvant therapy for rectal cancer: Implications for subsequent liver metastases and chemotherapy-associated liver injury. Surgery. 2026. PMID: 41926846. doi:10.1016/j.surg.2026.110179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。